ALS 8176

Drug Profile

ALS 8176

Alternative Names: AL 8176; ALS 008176; ALS8176; JNJ-64041575

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Alios BioPharma
  • Developer Alios BioPharma; Janssen Research & Development
  • Class Antivirals; Nucleosides
  • Mechanism of Action RNA replicase inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Respiratory syncytial virus infections
  • Preclinical Metapneumovirus infections; Parainfluenza virus infections

Most Recent Events

  • 09 May 2017 Johnson & Johnson is planning to file regulatory submissions for ALS 8176 in the US and EU in 2015 to 2019 (Johnson & Johnson pipeline; August 2015).
  • 10 Apr 2017 Phase-I clinical trials in Respiratory syncytial virus infections (In volunteers) in Germany (PO) (NCT03105986)
  • 04 Apr 2017 Janssen plans a phase I trial in Healthy volunteers in Germany (NCT03105986)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top